

4.0.3 DOC Cmte minutes

Dementia Guideline Committee meeting 7 – development

Date: 14/06/2016

Location: NICE offices, London

Minutes: Draft



Committee members present:	
Damien Longson (Chair)	Present for all
Louise Allan (LA)	Present for all
Richard Clibbens (RC)	Present for all
Carol Duff (CD)	Present for all
Kevin Minier (KMin)	Present for all
John O'Brien (JO)	Present for all
Ruth O'Dea (RO)	Present until item 6
Chris Roberts (CR)	Present for all
Jeremy Isaacs (JI)	Present for all
Tracey Wright (TW)	Present for all
Linda Clare (LC)	Present for all
Hannah Luff (HL)	Present from 11.30
Sandra Evans (SE)	Present until item 4
Sarah Partington (SP)	Present until item 6

In attendance:		
Vicky Gillis (VG)	ICG – Technical Analyst	Present for all
Sue Spiers (SS)	ICG – Associate Director	Present for all
Gabriel Rogers (GR)	ICG – Health Economic Advisor	Present for all
Joshua Pink (JP)	ICG – Technical Advisor	Present for all
Rupert Franklin (RF)	NICE – Commissioning programme manager	Present for all
Harry Allen (HA)	ICG – Expert Advisor	Present until item 4
Angela Parkin (AP)	NICE Medicines Advisor	Present for all
Louise Picton (LP)	NICE Medicines Advisor	Present until item 4
Louise Bate (LB)	NICE Associate Director – Medicines Prescribing Centre	Present until item 4
Elizabeth Barrett (EB)	NICE Information Specialist	Present for all
Daniel Davies (DD)	ICG - Project Manager	Present for all

4.0.3 DOC Cmte minutes

Observers:	
Adam O'Keefe	ICG – Project Manager
Jacqueline Durkin	ICG – Administrator
Louise Miller	NICE – Impact Analyst
Kate Moring	NICE – Business Analyst
Jayne Roberts	Accompanying lay member

Apologies:	
Joanne Brady	Committee member
Karen Harrison-Denning	Committee member
Paul Dunnery	Committee member
Louise Robinson	Committee member
Catherine Pascoe	Committee member
Kate Mitchell	Committee member

1. Welcome, apologies, objectives for the meeting, declaration of interests and minutes of previous meeting

The Chair welcomed the Committee members and attendees to the seventh meeting of the dementia guideline committee.

Apologies for the meeting were received as detailed above.

The Chair outlined the proposed objectives of the meeting and asked each attendee to declare any new conflicts.

No new interests were declared. It was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

2. Social Care sub-group update

SS provided an update on the establishment of a social care sub-group to the main committee noting that the applications received were currently being shortlisted for interview.

3. Parkinson's disease Guideline Review Question 20: What is the comparative effectiveness of rivastigmine, memantine, donepezil and galantamine for cognitive enhancement in dementia associated with Parkinson's disease?

LP recapped the review protocol and presented the evidence supporting Review Question 20 for the committee's consideration.

Following the presentation the committee discussed the evidence and drafted three recommendations for review question 20.

4.0.3 DOC Cmte minutes

4. Collaboration with the Prescribing Observatory for Mental Health
JP presented information on a proposed collaboration with the Prescribing Observatory for Mental Health, providing an update on possible inclusion of data from POMH in the evidence base for the guideline re prescribing behaviours He advised that the inclusion/exclusion of review questions had been reviewed following consultation with NICE's commissioning team
5. Discussion on potential call for evidence
The committee discussed the process for initiating a call for evidence to support development but agreed that this would not be necessary
6. Discussion on comments received on intercurrent illness chapter
The committee reviewed and agreed the linking evidence to recommendations table for review questions 20 and 21 on intercurrent illness.
7 & 8. Review Protocols
JP presented the review protocols for discussion and agreement with the committee. The committee agreed twelve review protocols. The NICE team agreed to circulate the updated list of review questions with the post-meeting papers.
9. Delirium assessments paper discussion
The committee discussed the recommendations in NICE's Delirium: prevention, diagnosis and management guideline (CG103) with regard to clinical assessments and whether a cross referral to these recommendations would be appropriate.
10. Any other business
There was no other business for discussion

Date of next meeting: Thursday 28 July 2016

Location of next meeting: NICE offices, Manchester